BioCryst Q2 ORLADEYO rev $81M (+24% YoY); on track for FY $320M; GAAP EPS ($0.40)

BIOCRYST PHARMACEUTICALS INC

2023-Q2 EPS reported -$0.68 revenue$151,269,000

ORLADEYO net revenue $81.0M in Q2 2023, up 24.2% YoY from $65.2M; total revenues $82.5M (+25.9% YoY).
GAAP net loss $75.3M ($0.40/share) vs $58.9M ($0.32/share) in Q2 2022; includes $29M one-time debt extinguishment fee.
Non-GAAP EPS ($0.24) after excluding the one-time fee; operating cash use $13.5M in Q2.
Reaffirmed FY 2023 ORLADEYO revenue guidance of >=$320M; peak revenue target $1B.
R&D day set for Nov 3, 2023 to introduce pipeline assets; BCX10013 trial enrollment in PNH expected by year-end.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

BIOCRYST PHARMACEUTICALS INC reported the second quarter ended June 30, 2023 results: revenue $82.5 million, net income Net loss for the second quarter of 2023 was $75.3 million, or $0.40 per share, EPS $0.40 per share. Guidance raised.

Period: the second quarter ended June 30, 2023
Revenue: $82.5 million
Net income: Net loss for the second quarter of 2023 was $75.3 million, or $0.40 per share
EPS: $0.40 per share
Guidance: raised
Result: reported results

Exact text from the filing

For the three months ended June 30, 2023, total revenues were $82.5 million, compared to $65.5 million in the second quarter of 2022 (+25.9 percent year-over-year (y-o-y)).

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

BIOCRYST PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001171843-23-004942

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.